We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novavax has announced preliminary data from a phase 1 trial of its COVID-19 vaccine NVX-CoV2373 in Australia that showed the vaccine generated a strong immune response. Read More
The National Institutes of Health (NIH) launched two clinical trials yesterday of Eli Lilly’s experimental monoclonal antibody LY-CoV555 for the treatment for COVID-19 patients. Read More
The head of the World Health Organization (WHO) cautioned Monday that no “silver bullet” for the coronavirus may emerge from the flurry of potential vaccines entering phase 3 trials. Read More
Severely ill COVID-19 patients given Relief Therapeutics’ RLF-100 (aviptadil) experienced rapid recovery in just three days, according to the company and its research partner NeuroRx. Read More
Eli Lilly has begun a phase 3 trial of its monoclonal antibody LY-CoV555 for the prevention of COVID-19 in residents and staff at long-term care facilities. Read More
Merck said it plans to launch two large phase 3 trials of its oral COVID-19 antiviral candidate MK-4482 in September and is also moving ahead with trials of two potential vaccines. Read More